Elder Tech Is the Other Half of Kid Tech

The phone rings at 4 p.m. on a Tuesday, in a quiet apartment in Queens. It isn't a family member. It isn't a doctor. It's Meela. She calls every Tuesday at 4, Wednesday at 11, and Sunday after dinner.

Last week we wrote about Kid Tech. Elder Tech is the same business pointed at the other end of the age curve, and in some ways it's the bigger one. The end user can't fully advocate for themselves. The buyer is someone else. The UX has to disappear. The trust posture is the entire product. And the moat is the relationship with the buyer, not the model.

The difference is that Kid Tech is a contested category. Elder Tech is barely a category at all -- even though the exits, the unicorns, and the payer dollars are already there.

The market is already paying

There are roughly 55 million Americans over 65. Almost 1 in 4 lives alone. The U.S. Surgeon General's 2023 advisory on loneliness classified social isolation as a public health crisis with mortality risk on par with smoking 15 cigarettes a day. AARP research shows 90% of people over 65 want to age in their own homes.

The buyer's wallet is already open. Medicare Advantage plans -- covering more than half of all Medicare-eligible Americans -- can now reimburse for "social engagement" and isolation interventions as supplemental benefits. CMS opened that door in 2020 and has widened it every year since. The companies just haven't fully shown up yet.

The proof points are already on the board

This isn't a speculative category. Real money has already moved:

• **GreatCall / Jitterbug** -- acquired by Best Buy for $800M in 2018. 900K paying subscribers at exit. Best Buy now runs Best Buy Health on the back of it.
• **Papa** -- companionship and "family on demand" for seniors. SoftBank-led Series D at $1.4B in 2021. Most of Papa's revenue runs through Medicare Advantage plans, not consumers.
• **Honor** -- tech-enabled home care, $370M in debt and equity in 2021, unicorn status. Backed by Baillie Gifford and T. Rowe Price.
• **Intuition Robotics (ElliQ)** -- the tabletop AI companion. \~$100M raised. Distributed through state aging-services contracts in New York, Florida, and elsewhere.
• **Sensi.AI** -- passive audio AI monitoring for in-home aging. $45M Series C in October 2025 led by Insight Partners.

These are not science projects. These are payer contracts, unicorn rounds, and clean strategic exits.

What's new in 2026

The new wave is voice-first, AI-native, and consumer-priced:

• **Meela** -- voice-first AI companion. No app, no install. The phone rings on a schedule. 80%+ retention past seven weeks, with early flags for mood shifts and confusion. The product is the phone ringing.
• **Ato** -- a $149 plug-in voice device sold direct to families. 60% of users make it a daily habit by week four. One cable to install. Family dashboard included.

Both companies are doing something the previous generation couldn't: deploying real-time conversational AI into a demographic that had been written off as too hard to reach.

Why voice changes the math

The first generation of senior tech failed for one reason -- it asked the user to learn the interface. Tablets with simplified icons. Apps with bigger fonts. Watches with SOS buttons. All required the user to climb a UX ladder they had no interest in climbing.

Voice removes the ladder. Conversation is the interface every human born in the 20th century already knows. The product doesn't ask the user to learn anything; it asks the model to learn the user.

That is why this category is alive in 2026 and was dead in 2016.

The clinical wedge

This is the part that matters for venture economics. A voice companion that talks to an 80-year-old five times a week is, whether the product wants to be or not, gathering signal -- mood, vocabulary, latency, missed medications, disorientation, repeated questions. That signal is medically relevant.

So the venture path isn't "consumer subscription." It's:

1. Earn trust as a companion.
2. Layer in soft monitoring.
3. Sell into Medicare Advantage as a supplemental benefit.
4. Become a payer-reimbursed clinical tool with consumer-grade UX.

That's a defensible, recurring-revenue, regulatory-moated business. It looks more like Hinge Health than Replika. Papa already proved the playbook works. The next wave is doing it with AI instead of a person on the other end of the phone.

Three open questions

Regulatory creep. When does a "companion" that flags confusion become a medical device under FDA SaMD rules? The agency has been quiet. They won't be forever.

Trust under attack. The same voice-cloning tech that powers Meela powers the grandchild scam, a $2.7B fraud category in 2023 according to the FTC. The companies that win this category will have to lead on trust before the bad actors weaponize the same primitives.

Where the value accrues. Is the durable asset the voice IP, the routine, the family-layer dashboard, or the payer contracts? Almost certainly the last two. But the first companies to win the consumer surface will have the cleanest shot at all four.

The kicker

Kid Tech and Elder Tech are the two categories society talks about most and designs for least.

The same architecture -- voice-first AI, hardware-as-trust-wrapper, software-as-personality, buyer-is-not-user -- is producing two different products at two ends of the age curve.

The Kid Tech version will be bigger in headlines.

The Elder Tech version may be bigger in revenue.